Immunic, Inc. IMUX
Immunic, Inc. (Nasdaq: IMUX) is a CNS/neurology/psychiatry drug developer. Its lead program, vidofludimus calcium (IMU-838), is in Phase 3 for relapsing multiple sclerosis. Its next catalyst on record is vidofludimus calcium: ENSURE-1 and ENSURE-2 topline data (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: vidofludimus calcium — ENSURE-1 and ENSURE-2 topline data (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vidofludimus calcium | relapsing MS | small molecule | Phase 3 |
| vidofludimus calcium | progressive MS | small molecule | Phase 3 |
| IMU-856 | GI disorders | small molecule | Phase 1 |
| IMU-381 | GI disorders | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.